Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase activity	GCNT3 GCNT1	1.98e-04	3	163	2	GO:0003829
GeneOntologyMolecularFunction	propionate-CoA ligase activity	ACSS2 ACSS3	3.93e-04	4	163	2	GO:0050218
GeneOntologyMolecularFunction	N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity	CHSY1 CHSY3	3.93e-04	4	163	2	GO:0050510
GeneOntologyMolecularFunction	short-chain fatty acid-CoA ligase activity	ACSS2 ACSS3	3.93e-04	4	163	2	GO:0031955
GeneOntologyMolecularFunction	branched-chain alpha-keto acid dehydrogenase activity	DBT DLD	3.93e-04	4	163	2	GO:0047101
GeneOntologyMolecularFunction	acetate-CoA ligase activity	ACSS2 ACSS3	3.93e-04	4	163	2	GO:0003987
GeneOntologyBiologicalProcess	vesicle transport along actin filament	WASL MYO5A MYO5B FNBP1L	4.71e-07	9	164	4	GO:0030050
GeneOntologyBiologicalProcess	actin filament-based transport	WASL MYO5A MYO5B FNBP1L	1.22e-06	11	164	4	GO:0099515
GeneOntologyBiologicalProcess	vesicle cytoskeletal trafficking	WASL MYO5A MYO5B FYCO1 FNBP1L KIF3A	1.54e-05	67	164	6	GO:0099518
Domain	Requiem/DPF_N_dom	DPF1 DPF2 DPF3	6.17e-07	3	160	3	IPR025750
Domain	Requiem_N	DPF1 DPF2 DPF3	6.17e-07	3	160	3	PF14051
Domain	GF_recep_IV	PCSK5 EGFR PCSK6	1.21e-05	6	160	3	PF14843
Domain	GF_recep_IV	PCSK5 EGFR PCSK6	1.21e-05	6	160	3	IPR032778
Domain	Furin_repeat	PCSK5 FRAS1 EGFR PCSK6	1.45e-05	18	160	4	IPR006212
Domain	FU	PCSK5 FRAS1 EGFR PCSK6	1.45e-05	18	160	4	SM00261
Domain	IQ	MYO1A MYO5A MYO5B PPEF1 SCN9A ASPM	3.25e-05	71	160	6	PF00612
Domain	-	PCSK5 MYCBP2 HECTD3 LAMA2 PCSK6 EPHA7	3.81e-05	73	160	6	2.60.120.260
Domain	IQ	MYO1A MYO5A MYO5B PPEF1 SCN9A ASPM	6.87e-05	81	160	6	SM00015
Domain	WD40	DCAF4L2 IFT172 CORO1C COPB2 EIPR1 WDR38 WDHD1 WDR35 WDR82 WDR72	8.14e-05	259	160	10	PF00400
Domain	WD40	DCAF4L2 IFT172 CORO1C COPB2 EIPR1 WDR38 WDHD1 WDR35 WDR82 WDR72	1.08e-04	268	160	10	SM00320
Domain	Tudor	ARID4A RNF17 TDRD7 ALG13	1.19e-04	30	160	4	IPR002999
Domain	WD40_repeat	DCAF4L2 IFT172 CORO1C COPB2 EIPR1 WDR38 WDHD1 WDR35 WDR82 WDR72	1.22e-04	272	160	10	IPR001680
Domain	IQ_motif_EF-hand-BS	MYO1A MYO5A MYO5B PPEF1 SCN9A ASPM	1.24e-04	90	160	6	IPR000048
Domain	WD_REPEATS_1	DCAF4L2 IFT172 CORO1C COPB2 EIPR1 WDR38 WDHD1 WDR35 WDR82 WDR72	1.46e-04	278	160	10	PS00678
Domain	IQ	MYO1A MYO5A MYO5B PPEF1 SCN9A ASPM	1.48e-04	93	160	6	PS50096
Domain	WD_REPEATS_2	DCAF4L2 IFT172 CORO1C COPB2 EIPR1 WDR38 WDHD1 WDR35 WDR82 WDR72	1.50e-04	279	160	10	PS50082
Domain	WD_REPEATS_REGION	DCAF4L2 IFT172 CORO1C COPB2 EIPR1 WDR38 WDHD1 WDR35 WDR82 WDR72	1.50e-04	279	160	10	PS50294
Domain	Galactose-bd-like	PCSK5 MYCBP2 HECTD3 LAMA2 PCSK6 EPHA7	1.57e-04	94	160	6	IPR008979
Domain	WD40_repeat_dom	DCAF4L2 IFT172 CORO1C COPB2 EIPR1 WDR38 WDHD1 WDR35 WDR82 WDR72	2.48e-04	297	160	10	IPR017986
Domain	ACAS_N	ACSS2 ACSS3	4.33e-04	4	160	2	PF16177
Domain	ACAS_N	ACSS2 ACSS3	4.33e-04	4	160	2	IPR032387
Domain	REJ	PKD1L2 PKDREJ	4.33e-04	4	160	2	PS51111
Domain	REJ_dom	PKD1L2 PKDREJ	4.33e-04	4	160	2	IPR014010
Domain	PLAC	PCSK5 ADAMTS12 PCSK6	5.41e-04	19	160	3	PS50900
Domain	PLAC	PCSK5 ADAMTS12 PCSK6	5.41e-04	19	160	3	IPR010909
Domain	-	SIGLEC12 IL10RA DSCAM MYCBP2 CADM4 IGSF5 CMYA5 PTGFRN LILRB1 MYOM2 KIR3DL2 IGSF21 IL23R TREML2 EPHA7	5.89e-04	663	160	15	2.60.40.10
Domain	-	DCAF4L2 IFT172 CORO1C COPB2 EIPR1 WDR38 WDHD1 WDR35 WDR82 WDR72	6.10e-04	333	160	10	2.130.10.10
Domain	RCC1	MYCBP2 ALS2 HERC5	6.32e-04	20	160	3	PF00415
Domain	WD40/YVTN_repeat-like_dom	DCAF4L2 IFT172 CORO1C COPB2 EIPR1 WDR38 WDHD1 WDR35 WDR82 WDR72	6.38e-04	335	160	10	IPR015943
Domain	Myosin_S1_N	MYO5A MYO5B	7.17e-04	5	160	2	IPR008989
Domain	PKD_2	PKD1L2 PKDREJ	7.17e-04	5	160	2	IPR003915
Domain	RCC1_1	MYCBP2 ALS2 HERC5	7.33e-04	21	160	3	PS00625
Domain	RCC1_2	MYCBP2 ALS2 HERC5	7.33e-04	21	160	3	PS00626
Domain	RCC1_3	MYCBP2 ALS2 HERC5	7.33e-04	21	160	3	PS50012
Domain	CUB	MASP1 CSMD3 LRP3 SEZ6	8.14e-04	49	160	4	PF00431
Domain	-	MYCBP2 ALS2 HERC5	8.43e-04	22	160	3	2.130.10.30
Domain	Reg_chr_condens	MYCBP2 ALS2 HERC5	8.43e-04	22	160	3	IPR000408
Domain	CUB	MASP1 CSMD3 LRP3 SEZ6	8.79e-04	50	160	4	SM00042
Domain	TUDOR	RNF17 TDRD7 ALG13	9.63e-04	23	160	3	PS50304
Domain	RCC1/BLIP-II	MYCBP2 ALS2 HERC5	9.63e-04	23	160	3	IPR009091
Domain	-	MASP1 CSMD3 LRP3 SEZ6	1.02e-03	52	160	4	2.60.120.290
Domain	Sushi	CFH MASP1 CSMD3 SEZ6	1.02e-03	52	160	4	PF00084
Domain	Dilute_dom	MYO5A MYO5B	1.07e-03	6	160	2	IPR002710
Domain	Peptidase_S8_Asp-AS	PCSK5 PCSK6	1.07e-03	6	160	2	IPR023827
Domain	DIL	MYO5A MYO5B	1.07e-03	6	160	2	PF01843
Domain	PKD/REJ-like	PKD1L2 PKDREJ	1.07e-03	6	160	2	IPR002859
Domain	REJ	PKD1L2 PKDREJ	1.07e-03	6	160	2	PF02010
Domain	DILUTE	MYO5A MYO5B	1.07e-03	6	160	2	PS51126
Domain	DIL	MYO5A MYO5B	1.07e-03	6	160	2	SM01132
Domain	CUB	MASP1 CSMD3 LRP3 SEZ6	1.10e-03	53	160	4	PS01180
Domain	Ig-like_fold	SIGLEC12 IL10RA DSCAM MYCBP2 CADM4 IGSF5 CMYA5 PTGFRN LILRB1 MYOM2 KIR3DL2 IGSF21 IL23R TREML2 EPHA7	1.11e-03	706	160	15	IPR013783
Domain	CCP	CFH MASP1 CSMD3 SEZ6	1.18e-03	54	160	4	SM00032
Domain	SUSHI	CFH MASP1 CSMD3 SEZ6	1.35e-03	56	160	4	PS50923
Domain	Sushi_SCR_CCP_dom	CFH MASP1 CSMD3 SEZ6	1.44e-03	57	160	4	IPR000436
Domain	CUB_dom	MASP1 CSMD3 LRP3 SEZ6	1.44e-03	57	160	4	IPR000859
Domain	APC_su10/DOC_dom	MYCBP2 HECTD3	1.49e-03	7	160	2	IPR004939
Domain	Peptidase_M13_C	MMEL1 MME	1.49e-03	7	160	2	IPR018497
Domain	DOC	MYCBP2 HECTD3	1.49e-03	7	160	2	PS51284
Domain	Peptidase_M13	MMEL1 MME	1.49e-03	7	160	2	IPR000718
Domain	Peptidase_M13_N	MMEL1 MME	1.49e-03	7	160	2	PF05649
Domain	Peptidase_M13_N	MMEL1 MME	1.49e-03	7	160	2	IPR008753
Domain	P_proprotein	PCSK5 PCSK6	1.49e-03	7	160	2	PF01483
Domain	S8_pro-domain	PCSK5 PCSK6	1.49e-03	7	160	2	IPR032815
Domain	ANAPC10	MYCBP2 HECTD3	1.49e-03	7	160	2	PF03256
Domain	PrprotnconvertsP	PCSK5 PCSK6	1.49e-03	7	160	2	IPR002884
Domain	Peptidase_M13	MMEL1 MME	1.49e-03	7	160	2	PF01431
Domain	-	PCSK5 PCSK6	1.49e-03	7	160	2	3.30.70.850
Domain	S8_pro-domain	PCSK5 PCSK6	1.49e-03	7	160	2	PF16470
Domain	APC10	MYCBP2 HECTD3	1.49e-03	7	160	2	SM01337
Domain	TUDOR	ARID4A RNF17 TDRD7	1.55e-03	27	160	3	SM00333
Domain	-	KLHL9 KLHL13 KLHL17	1.55e-03	27	160	3	2.130.10.80
Domain	VWC	COL5A2 FRAS1 CHRDL1	1.73e-03	28	160	3	PF00093
Domain	Glyco_trans_14	GCNT3 GCNT1	1.97e-03	8	160	2	IPR003406
Domain	Chond_GalNAc	CHSY1 CHSY3	1.97e-03	8	160	2	IPR008428
Domain	CHGN	CHSY1 CHSY3	1.97e-03	8	160	2	PF05679
Domain	Branch	GCNT3 GCNT1	1.97e-03	8	160	2	PF02485
Domain	Growth_fac_rcpt_	PCSK5 FRAS1 THBS3 EGFR PCSK6 EPHA7	2.27e-03	156	160	6	IPR009030
Domain	Peptidase_S8_His-AS	PCSK5 PCSK6	2.52e-03	9	160	2	IPR022398
Domain	Peptidase_S8_Ser-AS	PCSK5 PCSK6	2.52e-03	9	160	2	IPR023828
Domain	WD40_repeat_CS	CORO1C EIPR1 WDR38 WDHD1 WDR82 WDR72	2.92e-03	164	160	6	IPR019775
Domain	Gal_Oxidase_b-propeller	KLHL9 KLHL13 KLHL17	3.04e-03	34	160	3	IPR015916
Domain	Peptidase_S8_subtilisin-rel	PCSK5 PCSK6	3.14e-03	10	160	2	IPR015500
Domain	SUBTILASE_ASP	PCSK5 PCSK6	3.14e-03	10	160	2	PS00136
Domain	SUBTILASE_HIS	PCSK5 PCSK6	3.14e-03	10	160	2	PS00137
Domain	SUBTILASE_SER	PCSK5 PCSK6	3.14e-03	10	160	2	PS00138
Domain	IG	SIGLEC12 DSCAM CADM4 IGSF5 PTGFRN LILRB1 MYOM2 KIR3DL2 IGSF21 TREML2	3.46e-03	421	160	10	SM00409
Domain	Ig_sub	SIGLEC12 DSCAM CADM4 IGSF5 PTGFRN LILRB1 MYOM2 KIR3DL2 IGSF21 TREML2	3.46e-03	421	160	10	IPR003599
Domain	VWFC_1	COL5A2 FRAS1 CHRDL1	3.58e-03	36	160	3	PS01208
Domain	-	PCSK5 PCSK6	3.81e-03	11	160	2	3.40.50.200
Domain	Peptidase_S8/S53_dom	PCSK5 PCSK6	3.81e-03	11	160	2	IPR000209
Domain	PKD_channel	PKD1L2 PKDREJ	3.81e-03	11	160	2	PF08016
Domain	Peptidase_S8	PCSK5 PCSK6	3.81e-03	11	160	2	PF00082
Domain	PKD1_2_channel	PKD1L2 PKDREJ	3.81e-03	11	160	2	IPR013122
Domain	Myosin_head_motor_dom	MYO1A MYO5A MYO5B	4.18e-03	38	160	3	IPR001609
Domain	VWFC_2	COL5A2 FRAS1 CHRDL1	4.18e-03	38	160	3	PS50184
Domain	MYOSIN_MOTOR	MYO1A MYO5A MYO5B	4.18e-03	38	160	3	PS51456
Domain	VWC	COL5A2 FRAS1 CHRDL1	4.18e-03	38	160	3	SM00214
Domain	Myosin_head	MYO1A MYO5A MYO5B	4.18e-03	38	160	3	PF00063
Domain	MYSc	MYO1A MYO5A MYO5B	4.18e-03	38	160	3	SM00242
Pubmed	Regulation of muscle development by DPF3, a novel histone acetylation and methylation reader of the BAF chromatin remodeling complex.	DPF1 DPF2 DPF3	1.07e-07	3	166	3	18765789
Pubmed	The d4 gene family in the human genome.	DPF1 DPF2 DPF3	1.07e-07	3	166	3	8812431
Pubmed	Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.	MYC TXNIP EGFR	1.07e-07	3	166	3	32356386
Pubmed	Transcriptome analysis of mouse stem cells and early embryos.	DCAF4L2 HECTD4 ALS2 NCKAP5 CFI MTMR10 FRMD4B MDN1 ASPM WDR82 EPHA7 KLHL17	2.01e-07	363	166	12	14691545
Pubmed	A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity.	MYC ARHGEF12 KLHL9 EGFR PIK3CA KLHL13	3.23e-06	84	166	6	34591642
Pubmed	Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer.	MYC FLII MYO5A MYO5B MYCBP2 HECTD4 DHX15 ABCD3 MME	5.48e-06	264	166	9	32814769
Pubmed	Mammalian SWI/SNF collaborates with a polycomb-associated protein to regulate male germline transcription in the mouse.	DPF1 ATR DPF2 DPF3	1.25e-05	30	166	4	31043422
Pubmed	Heritability and genome-wide association study to assess genetic differences between advanced age-related macular degeneration subtypes.	CFH CFI SOD2	1.25e-05	10	166	3	22705344
Pubmed	PTEN identified as important risk factor of chronic obstructive pulmonary disease.	MYC CFH IL10RA MASP1 COMT MYO5A CHEK1 EGFR SOD2 CXCR1	1.38e-05	374	166	10	19625176
Pubmed	Telencephalic embryonic subtractive sequences: a unique collection of neurodevelopmental genes.	ZNF562 NCKAP5 FNBP1L EPM2AIP1 DHX15 KLHL9 TOP2A	1.53e-05	165	166	7	16107646
Pubmed	Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway.	MYC CFH IL10RA MASP1 COMT MYO5A CHEK1 EGFR SOD2 CXCR1	1.62e-05	381	166	10	18676680
Pubmed	Double plant homeodomain (PHD) finger proteins DPF3a and -3b are required as transcriptional co-activators in SWI/SNF complex-dependent activation of NF-κB RelA/p50 heterodimer.	DPF1 DPF2 DPF3	1.71e-05	11	166	3	22334708
Pubmed	Comparative interactome analysis of α-arrestin families in human and Drosophila.	MYO5A COPB2 INPP5F ASH2L TXNIP KIDINS220 WDHD1 ABCD3 WDR82	2.12e-05	313	166	9	38270169
Pubmed	Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.	MYC EGFR	2.26e-05	2	166	2	18559552
Pubmed	Activation of ATR-Chk1 pathway facilitates EBV-mediated transformation of primary tonsillar B-cells.	ATR CHEK1	2.26e-05	2	166	2	28031537
Pubmed	Myogenesis defect due to Toca-1 knockdown can be suppressed by expression of N-WASP.	WASL FNBP1L	2.26e-05	2	166	2	24861867
Pubmed	Associations of ATR and CHEK1 single nucleotide polymorphisms with breast cancer.	ATR CHEK1	2.26e-05	2	166	2	23844225
Pubmed	Mangiferin induces cell cycle arrest at G2/M phase through ATR-Chk1 pathway in HL-60 leukemia cells.	ATR CHEK1	2.26e-05	2	166	2	25966274
Pubmed	EGFR and MYC gene copy number aberrations are more common in squamous cell carcinoma than keratoacanthoma: a FISH study.	MYC EGFR	2.26e-05	2	166	2	23521519
Pubmed	Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.	MYC CHEK1	2.26e-05	2	166	2	26988986
Pubmed	Regulation of epidermal growth factor receptor by activated H-ras and V-myc oncogenes in mouse Balb/3T3 cells: possible roles of AP-1.	MYC EGFR	2.26e-05	2	166	2	8622882
Pubmed	Withaferin A inhibits expression of ataxia telangiectasia and Rad3-related kinase and enhances sensitivity of human breast cancer cells to cisplatin.	ATR CHEK1	2.26e-05	2	166	2	31441116
Pubmed	Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.	ATR CHEK1	2.26e-05	2	166	2	29138515
Pubmed	Targeted inhibition of ATR or CHEK1 reverses radioresistance in oral squamous cell carcinoma cells with distal chromosome arm 11q loss.	ATR CHEK1	2.26e-05	2	166	2	24327542
Pubmed	Principles of mitoribosomal small subunit assembly in eukaryotes.	MCAT METTL17	2.26e-05	2	166	2	36482135
Pubmed	Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R.	ATR CHEK1	2.26e-05	2	166	2	12738771
Pubmed	Cleavage-mediated activation of Chk1 during apoptosis.	ATR CHEK1	2.26e-05	2	166	2	18550533
Pubmed	Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.	ATR CHEK1	2.26e-05	2	166	2	26748709
Pubmed	Chondroitin sulfate synthase-3. Molecular cloning and characterization.	CHSY1 CHSY3	2.26e-05	2	166	2	12907687
Pubmed	c-Myc-driven glycolysis via TXNIP suppression is dependent on glutaminase-MondoA axis in prostate cancer.	MYC TXNIP	2.26e-05	2	166	2	30103944
Pubmed	The nucleolus stress response is coupled to an ATR-Chk1-mediated G2 arrest.	ATR CHEK1	2.26e-05	2	166	2	23447702
Pubmed	In silico based investigation of dynamic variations in neprilysin (NEP and NEP2) proteins for extracting the point of specificity.	MMEL1 MME	2.26e-05	2	166	2	26846903
Pubmed	Regulation of neuronal morphology by Toca-1, an F-BAR/EFC protein that induces plasma membrane invagination.	WASL FNBP1L	2.26e-05	2	166	2	16885158
Pubmed	Phosphorylation and stabilization of topoisomerase IIα protein by p38γ mitogen-activated protein kinase sensitize breast cancer cells to its poisons.	MAPK12 TOP2A	2.26e-05	2	166	2	21878638
Pubmed	Reduced kinase D‑interacting substrate of 220 kDa (Kidins220) in pancreatic cancer promotes EGFR/ERK signalling and disease progression.	KIDINS220 EGFR	2.26e-05	2	166	2	33955519
Pubmed	PIK3CA mutations and specific treatment: do not forget lessons from RAS mutations and EGFR targeting.	EGFR PIK3CA	2.26e-05	2	166	2	31970497
Pubmed	ATR-Chk1 activation mitigates replication stress caused by mismatch repair-dependent processing of DNA damage.	ATR CHEK1	2.26e-05	2	166	2	29378956
Pubmed	Human neprilysin-2 (NEP2) and NEP display distinct subcellular localisations and substrate preferences.	MMEL1 MME	2.26e-05	2	166	2	18539150
Pubmed	High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers.	EGFR PIK3CA	2.26e-05	2	166	2	26680641
Pubmed	Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently overexpress EGFR protein without EGFR gene amplification.	EGFR TOP2A	2.26e-05	2	166	2	20688355
Pubmed	ATR-Chk1 pathway inhibition promotes apoptosis after UV treatment in primary human keratinocytes: potential basis for the UV protective effects of caffeine.	ATR CHEK1	2.26e-05	2	166	2	19242509
Pubmed	Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.	ATR CHEK1	2.26e-05	2	166	2	27693461
Pubmed	Mucin biosynthesis: epidermal growth factor downregulates core 2 enzymes in a human airway adenocarcinoma cell line.	GCNT3 GCNT1	2.26e-05	2	166	2	12600830
Pubmed	The p110α and p110β isoforms of class I phosphatidylinositol 3-kinase are involved in toll-like receptor 5 signaling in epithelial cells.	PIK3CA TLR5	2.26e-05	2	166	2	20953381
Pubmed	Dermatopontin inhibits papillary thyroid cancer cell proliferation through MYC repression.	MYC DPT	2.26e-05	2	166	2	30391671
Pubmed	Identification of an isoform with an extremely large Cys-rich region of PC6, a Kex2-like processing endoprotease.	PCSK5 PCSK6	2.26e-05	2	166	2	8335106
Pubmed	ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.	ATR CHEK1	2.26e-05	2	166	2	26657501
Pubmed	Consequences of direct versus indirect activation of epidermal growth factor receptor in intestinal epithelial cells are dictated by protein-tyrosine phosphatase 1B.	PTPN1 EGFR	2.26e-05	2	166	2	17339316
Pubmed	Development of "substrate-trapping" mutants to identify physiological substrates of protein tyrosine phosphatases.	PTPN1 EGFR	2.26e-05	2	166	2	9050838
Pubmed	Access to the nucleus and functional association with c-Myc is required for the full oncogenic potential of ΔEGFR/EGFRvIII.	MYC EGFR	2.26e-05	2	166	2	23250739
Pubmed	Structure and expression of two members of the d4 gene family in mouse.	DPF1 DPF2	2.26e-05	2	166	2	10602997
Pubmed	Parvovirus B19 infection of human primary erythroid progenitor cells triggers ATR-Chk1 signaling, which promotes B19 virus replication.	ATR CHEK1	2.26e-05	2	166	2	21680529
Pubmed	Poly(amido amine) is an ideal carrier of miR-7 for enhancing gene silencing effects on the EGFR pathway in U251 glioma cells.	LILRB1 EGFR	2.26e-05	2	166	2	23404538
Pubmed	Regulatory components of the alternative complement pathway in endothelial cell cytoplasm, factor H and factor I, are not packaged in Weibel-Palade bodies.	CFH CFI	2.26e-05	2	166	2	25803806
Pubmed	Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.	EGFR PIK3CA	2.26e-05	2	166	2	26334752
Pubmed	Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.	MYC PIK3CA	2.26e-05	2	166	2	21822287
Pubmed	Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia.	MYC PIK3CA	2.26e-05	2	166	2	22623730
Pubmed	Reduced ATR or Chk1 expression leads to chromosome instability and chemosensitization of mismatch repair-deficient colorectal cancer cells.	ATR CHEK1	2.26e-05	2	166	2	19570909
Pubmed	Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma.	EGFR PIK3CA	2.26e-05	2	166	2	19272638
Pubmed	Membrane contacts between endosomes and ER provide sites for PTP1B-epidermal growth factor receptor interaction.	PTPN1 EGFR	2.26e-05	2	166	2	20118922
Pubmed	Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP.	MYC TXNIP	2.26e-05	2	166	2	25870263
Pubmed	Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells.	ATR CHEK1	2.26e-05	2	166	2	21383502
Pubmed	Sustained Activation of Rho GTPases Promotes a Synthetic Pulmonary Artery Smooth Muscle Cell Phenotype in Neprilysin Null Mice.	MMEL1 MME	2.26e-05	2	166	2	29191928
Pubmed	Association between vitamin D status and age-related macular degeneration by genetic risk.	CFH CFI	2.26e-05	2	166	2	26312598
Pubmed	Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.	EGFR PIK3CA	2.26e-05	2	166	2	21258250
Pubmed	Determinants of substrate recognition in the protein-tyrosine phosphatase, PTP1.	PTPN1 EGFR	2.26e-05	2	166	2	8621392
Pubmed	Structural basis for phosphotyrosine peptide recognition by protein tyrosine phosphatase 1B.	PTPN1 EGFR	2.26e-05	2	166	2	7540771
Pubmed	EGFR, COX2, p-AKT expression and PIK3CA mutation in distal extrahepatic bile duct carcinoma.	EGFR PIK3CA	2.26e-05	2	166	2	27020207
Pubmed	EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.	MYC EGFR	2.26e-05	2	166	2	30770740
Pubmed	ATR and a Chk1-Aurora B pathway coordinate postmitotic genome surveillance with cytokinetic abscission.	ATR CHEK1	2.26e-05	2	166	2	25904336
Pubmed	Activation of PTP1B/EGFR signaling and cytotoxicity during combined exposure to ambient electrophiles in A431 cells.	PTPN1 EGFR	2.26e-05	2	166	2	33814511
Pubmed	ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress.	ATR CHEK1	2.26e-05	2	166	2	19119425
Pubmed	4-Hydroxynonenal induces G2/M phase cell cycle arrest by activation of the ataxia telangiectasia mutated and Rad3-related protein (ATR)/checkpoint kinase 1 (Chk1) signaling pathway.	ATR CHEK1	2.26e-05	2	166	2	23733185
Pubmed	Identification of a large Myc-binding protein that contains RCC1-like repeats.	MYC MYCBP2	2.26e-05	2	166	2	9689053
Pubmed	An ATR and CHK1 kinase signaling mechanism that limits origin firing during unperturbed DNA replication.	ATR CHEK1	2.26e-05	2	166	2	31209037
Pubmed	Molecular cloning of rat acss3 and characterization of mammalian propionyl-CoA synthetase in the liver mitochondrial matrix.	ACSS2 ACSS3	2.26e-05	2	166	2	28003429
Pubmed	Activation of β-catenin by oncogenic PIK3CA and EGFR promotes resistance to glucose deprivation by inducing a strong antioxidant response.	EGFR PIK3CA	2.26e-05	2	166	2	22662165
Pubmed	Use of time-resolved FRET to validate crystal structure of complement regulatory complex between C3b and factor H (N terminus).	CFH CFI	2.26e-05	2	166	2	21936007
Pubmed	An overactivated ATR/CHK1 pathway is responsible for the prolonged G2 accumulation in irradiated AT cells.	ATR CHEK1	2.26e-05	2	166	2	12791699
Pubmed	The Toca-1-N-WASP complex links filopodial formation to endocytosis.	WASL FNBP1L	2.26e-05	2	166	2	19213734
Pubmed	HECTD3 promotes gastric cancer progression by mediating the polyubiquitination of c-MYC.	MYC HECTD3	2.26e-05	2	166	2	35397617
Pubmed	Regulation of protein tyrosine phosphatase 1B in intact cells by S-nitrosothiols.	PTPN1 EGFR	2.26e-05	2	166	2	12573287
Pubmed	Cerd4, third member of the d4 gene family: expression and organization of genomic locus.	DPF2 DPF3	2.26e-05	2	166	2	11845289
Pubmed	Bacterial actin assembly requires toca-1 to relieve N-wasp autoinhibition.	WASL FNBP1L	2.26e-05	2	166	2	18191793
Pubmed	HSP60 overexpression increases the protein levels of the p110α subunit of phosphoinositide 3-kinase and c-Myc.	MYC PIK3CA	2.26e-05	2	166	2	26174078
Pubmed	Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR.	TBC1D16 EGFR	2.26e-05	2	166	2	26030178
Pubmed	Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.	EGFR PIK3CA	2.26e-05	2	166	2	28446642
Pubmed	The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR.	EGFR PIK3CA	2.26e-05	2	166	2	27317099
Pubmed	Cell-surface processing of extracellular human immunodeficiency virus type 1 Vpr by proprotein convertases.	PCSK5 PCSK6	2.26e-05	2	166	2	18061232
Pubmed	Acidosis decreases c-Myc oncogene expression in human lymphoma cells: a role for the proton-sensing G protein-coupled receptor TDAG8.	MYC GPR65	2.26e-05	2	166	2	24152439
Pubmed	Myosin Va and Endoplasmic Reticulum Calcium Channel Complex Regulates Membrane Export during Axon Guidance.	MYO5A RYR3	2.26e-05	2	166	2	27134178
Pubmed	A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.	EGFR PIK3CA	2.26e-05	2	166	2	24453288
Pubmed	Genetic mutation screen in early non--small-cell lung cancer (NSCLC) specimens.	EGFR PIK3CA	2.26e-05	2	166	2	24370118
Pubmed	Investigation of the Interaction between Cdc42 and Its Effector TOCA1: HANDOVER OF Cdc42 TO THE ACTIN REGULATOR N-WASP IS FACILITATED BY DIFFERENTIAL BINDING AFFINITIES.	WASL FNBP1L	2.26e-05	2	166	2	27129201
Pubmed	Identification and functional expression of a new member of the mammalian Kex2-like processing endoprotease family: its striking structural similarity to PACE4.	PCSK5 PCSK6	2.26e-05	2	166	2	8468318
Pubmed	Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit.	ATR CHEK1	2.26e-05	2	166	2	17015476
Pubmed	COMT and SCN9A gene variants do not contribute to chronic low back pain in Mexican-Mestizo patients.	COMT SCN9A	2.26e-05	2	166	2	38329587
Pubmed	An ATR- and Chk1-dependent S checkpoint inhibits replicon initiation following UVC-induced DNA damage.	ATR CHEK1	2.26e-05	2	166	2	12446774
Pubmed	Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer.	ATR CHEK1	2.26e-05	2	166	2	25468710
Pubmed	Genetically engineered fusion of MAP-1 and factor H domains 1-5 generates a potent dual upstream inhibitor of both the lectin and alternative complement pathways.	CFH MASP1	2.26e-05	2	166	2	26260032
Interaction	NIPAL4 interactions	MYC IL10RA COMT EGFR LHFPL5	7.00e-07	22	160	5	int:NIPAL4
Interaction	HERC2 interactions	MYC FLII MYCBP2 CORO1C COPB2 HECTD4 ARHGEF12 NCKAP5 DHX15 TXNIP PTPN1 EGFR ASPM OSBPL6 EPHA7	1.20e-05	503	160	15	int:HERC2
Interaction	CLEC12B interactions	PCSK5 TPST1 TUSC3 CHSY1 GCNT1 PTGFRN EGFR ST6GALNAC3 CHSY3	1.67e-05	184	160	9	int:CLEC12B
GeneFamily	WD repeat domain containing	DCAF4L2 IFT172 CORO1C COPB2 EIPR1 WDR38 WDHD1 WDR35 WDR82 WDR72	1.14e-05	262	122	10	362
GeneFamily	ATP binding cassette subfamily D\|GOLD domain containing	FYCO1 ABCD3	1.35e-04	3	122	2	1062
GeneFamily	Myosins, class V	MYO5A MYO5B	1.35e-04	3	122	2	1100
GeneFamily	Immunoglobulin like domain containing	DSCAM CADM4 IGSF5 PTGFRN CEACAM18 MYOM2 IGSF21	3.37e-04	193	122	7	594
GeneFamily	Hyalectan proteoglycans\|V-set domain containing\|Sushi domain containing\|C-type lectin domain containing	CFH MASP1 CSMD3 SEZ6	5.91e-04	57	122	4	1179
GeneFamily	Adenosine receptors\|V-set domain containing	SIGLEC12 CADM4 PTGFRN CEACAM18 IGSF21 TREML2	8.37e-04	163	122	6	590
GeneFamily	Glucosaminyl (N-acetyl) transferases/xylosyltransferases	GCNT3 GCNT1	1.23e-03	8	122	2	441
GeneFamily	Proprotein convertase subtilisin/kexin family	PCSK5 PCSK6	1.58e-03	9	122	2	973
GeneFamily	Tudor domain containing	RNF17 TDRD7 ALG13	1.97e-03	37	122	3	780
GeneFamily	Kelch like\|BTB domain containing	KLHL9 KLHL13 KLHL17	2.84e-03	42	122	3	617
GeneFamily	PHD finger proteins	DPF1 DPF2 ASH2L DPF3	3.23e-03	90	122	4	88
GeneFamily	Protein phosphatase catalytic subunits\|EF-hand domain containing	PPEF1 PPP6C	3.36e-03	13	122	2	693
GeneFamily	C-type lectin domain family	CLEC9A CLEC17A MRC2	3.92e-03	47	122	3	494
GeneFamily	ADAM metallopeptidase domain containing\|CD molecules	IL10RA CLEC9A PTGFRN LILRB1 MRC2 MME KIR3DL2 CXCR1	5.28e-03	394	122	8	471
GeneFamily	Beta 4-glycosyltransferases	CHSY1 CHSY3	5.75e-03	17	122	2	425
Coexpression	MANNO_MIDBRAIN_NEUROTYPES_HRGL2A	GPM6A MASP1 ABAT COMT CADM4 ABHD2 IGSF5 NCKAP5 CSMD3 WDR38 TMEM232 EGFR MRC2 PCSK6 OSBPL6	6.44e-06	600	165	15	M39055
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_DN	MYC COL5A2 TPST1 ATR MYCBP2 ARID4A CHSY1 FNBP1L GCNT1 INPP5F TDRD7 DHX15 PTPN1 KIDINS220 MDN1 WDHD1 EGFR TOP2A	8.15e-06	856	165	18	M4500
Coexpression	DESCARTES_FETAL_SPLEEN_MYELOID_CELLS	IL10RA CLEC9A DSCAM TMEM63C NCKAP5 LILRB1 IGSF21	2.10e-05	132	165	7	M40289
Coexpression	GSE41176_WT_VS_TAK1_KO_ANTI_IGM_STIM_BCELL_1H_UP	ENTPD7 GCNT3 HECTD4 HORMAD1 PTGFRN NADSYN1 MCAT DNAH8	3.84e-05	198	165	8	M9934
Coexpression	GSE21927_SPLENIC_VS_TUMOR_MONOCYTES_FROM_C26GM_TUMOROUS_MICE_BALBC_DN	ABAT MYCBP2 EPM2AIP1 TXNIP THBS3 KMT5B PIK3CA ALG13	3.84e-05	198	165	8	M7605
Coexpression	GAO_LARGE_INTESTINE_24W_C1_DCLK1POS_PROGENITOR	MYC COL5A2 TPST1 DPT LAMA2 MRC2	3.93e-05	99	165	6	M39152
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN	MYC COL5A2 ATR MYCBP2 CHSY1 FNBP1L INPP5F TDRD7 DHX15 MDN1 EGFR TOP2A	4.21e-05	466	165	12	M13522
CoexpressionAtlas	DevelopingGonad_P2_ovary_emap-30224_top-relative-expression-ranked_500	CFH MYO5A RNF17 HORMAD1 KIF3A TXNIP NLRP14 DPF3 PCSK6 FAM47E DNAH8 ALG13	3.37e-05	379	161	12	gudmap_developingGonad_P2_ovary_500
CoexpressionAtlas	FacebaseRNAseq_e10.5_Neural Epithelium Overlying Medial Eminence_top-relative-expression-ranked_1000_k-means-cluster#4	DPF1 GPM6A ARID4A ARHGEF12 NCKAP5 INPP5F FRMD4B PTPN1 SNAPC3	5.69e-05	225	161	9	Facebase_RNAseq_e10.5_Neural Epithelium Overlying Medial Eminence_1000_K4
CoexpressionAtlas	facebase_RNAseq_e14.5_palate_poster_distal_ERK2_WT_2500_K1	DPF1 PCSK5 GPM6A COL5A2 TPST1 DPT MASP1 DENND4A ARID4A LAMA2 FYCO1 PTGFRN MTMR10 ADAMTS12 SIAE THBS3 KCNT2 EGFR MRC2 PNPLA8 MME EPHA7	7.23e-05	1166	161	22	facebase_RNAseq_e14.5_palate_poster_distal_ERK2_WT_2500_K1
CoexpressionAtlas	dev gonad_e12.5_M_InterstitLeydig_MafB_top-relative-expression-ranked_1000	CFH PCSK5 GPM6A MASP1 MYO1A LAMA2 CHEK1 FRMD4B EGFR MRC2 KLHL13 PCSK6 ASPM MME TOP2A ALDH7A1 EPHA7	7.73e-05	768	161	17	gudmap_dev gonad_e12.5_M_InterstitLeydig_MafB_1000
CoexpressionAtlas	DevelopingGonad_P2_ovary_emap-30224_top-relative-expression-ranked_1000	CFH WASL GCNT3 MYO5A CHEK1 RNF17 HORMAD1 FRMD4B KIF3A TXNIP NLRP14 DPF3 PCSK6 FAM47E SNAPC3 DNAH8 ALG13	7.98e-05	770	161	17	gudmap_developingGonad_P2_ovary_1000
ToppCell	facs-Trachea-nan-3m-Mesenchymal-fibroblast\|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CFH PCSK5 COL5A2 TPST1 DPT LAMA2 PTGFRN THBS3 EGFR MRC2 PCSK6	2.36e-10	198	166	11	0dc7d59a07428a7b7e8bdc81f0e2417dd4ce3cf2
ToppCell	facs-Mammary_Gland-Mammary_Gland-3m-Mesenchymal-stromal_cell\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CFH COL5A2 DPT LAMA2 EMILIN1 ADAMTS12 THBS3 MRC2 CHRDL1	3.36e-08	185	166	9	00258f458cbf6d36449db95528a6b5038d731d2d
ToppCell	facs-Mammary_Gland-Mammary_Gland-3m-Mesenchymal-stromal_cell\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CFH COL5A2 DPT LAMA2 EMILIN1 ADAMTS12 THBS3 MRC2 CHRDL1	3.36e-08	185	166	9	3cd0686a14e734a0f243070ab939adcb4c454478
ToppCell	facs-Mammary_Gland-Mammary_Gland-3m-Mesenchymal\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CFH COL5A2 DPT LAMA2 EMILIN1 ADAMTS12 THBS3 MRC2 CHRDL1	3.36e-08	185	166	9	a94694e226856bc5b168464f52d76004145717a5
ToppCell	facs-Aorta-Heart-3m-Mesenchymal-fibroblast\|Aorta / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	COL5A2 DPT FRAS1 NCKAP5 PTGFRN THBS3 MRC2 PCSK6 EPHA7	4.42e-08	191	166	9	9214655dca96d766737c9f30b624d7fe7050342e
ToppCell	Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_2_cell\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	CFH COL5A2 TPST1 DPT LAMA2 KCNT2 MRC2 KLHL13 CHRDL1	4.62e-08	192	166	9	8d56e360ebc624ca4cd7f0af4f3cc599c244f134
ToppCell	COPD-Stromal-Myofibroblast\|World / Disease state, Lineage and Cell class	CFH COL5A2 DPT LAMA2 EMILIN1 ADAMTS12 EGFR MRC2 CHRDL1	5.76e-08	197	166	9	d51f484b4e01ac64233950d0b97fa88825ea1dbb
ToppCell	tumor_Lung-Fibroblasts-COL14A1+_matrix_FBs\|tumor_Lung / Location, Cell class and cell subclass	CFH COL5A2 TPST1 DPT LAMA2 PTGFRN EMILIN1 MRC2 CHRDL1	6.02e-08	198	166	9	74f2c7ef702b25a5b99e56121229e678ed992524
ToppCell	Parenchymal-10x5prime-Stromal-Fibroblastic-Fibro_alveolar\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	CFH COL5A2 DPT FRAS1 LAMA2 EMILIN1 ADAMTS12 MRC2 CHRDL1	6.56e-08	200	166	9	8c62f05c6042f24287a73fbdf80ff4a56f7ff403
ToppCell	(5)_Fibroblast-E\|World / Lung cell shreds - cell class (v4) and cell subclass (v4)	CFH COL5A2 DPT ARID4A LAMA2 CFI THBS3 MRC2 CHRDL1	6.56e-08	200	166	9	75e5ecb05e965e24d569aa2ef5cdf740b1528c06
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	GPM6A FRAS1 ACADL DSCAM MYO5B FNBP1L PEBP4 EGFR	2.92e-07	173	166	8	b799c06a6a5754668e789f70c0c8bc1508568575
ToppCell	facs-Heart-LV-18m-Mesenchymal-fibroblast_of_cardiac_tissue\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DPT IFT172 LAMA2 EMILIN1 EGFR MRC2 PCSK6 MME	3.33e-07	176	166	8	fee4e0f32aaf77294040c7af6c1f503571750d43
ToppCell	facs-Heart-LV-18m-Mesenchymal-fibroblast_of_cardiac_tissue\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DPT IFT172 LAMA2 EMILIN1 EGFR MRC2 PCSK6 MME	3.33e-07	176	166	8	f25251abd4ef9fb077a978f9f9f658af58e4e0d2
ToppCell	5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts-Alveolar_fibroblasts_L.2.1.1.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CFH COL5A2 DPT LAMA2 EMILIN1 ADAMTS12 MRC2 CHRDL1	5.07e-07	186	166	8	5473283fb95cee556b1f6934cf72169b676b5bcc
ToppCell	COVID-19-kidney-Stressed_PCT\|kidney / Disease (COVID-19 only), tissue and cell type	PCSK5 NCKAP5 ACSS2 DPF3 OSBPL6 MME EPHA7 WDR72	5.28e-07	187	166	8	acd305475f3609800af0d7bc68d83ef41228080b
ToppCell	COVID-19-Heart-Fib_1\|COVID-19 / Disease (COVID-19 only), tissue and cell type	CFH COL5A2 DPT LAMA2 KCNT2 EGFR MRC2 PCSK6	5.49e-07	188	166	8	fe361215f4ba841aa5e1e581fb56f2f4d3ccd201
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	CFH COL5A2 LAMA2 EMILIN1 ADAMTS12 KCNT2 MRC2 DNAH8	5.72e-07	189	166	8	71397e993a77d70b2eeede240bdfc7660b558987
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast-\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	CFH COL5A2 LAMA2 EMILIN1 ADAMTS12 KCNT2 MRC2 DNAH8	5.72e-07	189	166	8	4eea4759520c312bd17a681034d8074e47093d2b
ToppCell	5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Peribronchial_fibroblasts\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CFH COL5A2 DPT LAMA2 EMILIN1 ADAMTS12 MRC2 CHRDL1	6.19e-07	191	166	8	0fae1c2ef9f83ac7721d0a9d69455bf97eed9257
ToppCell	facs-Trachea-3m-Mesenchymal-fibroblast\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CFH COL5A2 DPT LAMA2 PTGFRN THBS3 EGFR PCSK6	6.44e-07	192	166	8	321850b0f881420c2d57d3e825e365c82fa511ab
ToppCell	facs-Trachea-3m-Mesenchymal-fibroblast-fibroblast_of_trachea\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CFH COL5A2 DPT LAMA2 PTGFRN THBS3 EGFR PCSK6	6.44e-07	192	166	8	cf2765d8bc074f7f9ee864eae632a3b705175842
ToppCell	COVID-19-Heart-Fib_+_EC_+_Pericyte\|Heart / Disease (COVID-19 only), tissue and cell type	CFH PCSK5 COL5A2 LAMA2 KCNT2 EGFR MRC2 ST6GALNAC3	6.44e-07	192	166	8	60b1312e84f6d6448365a952469c506c00b5fe93
ToppCell	facs-Lung-3m-Mesenchymal\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CFH COL5A2 TPST1 DPT LAMA2 EMILIN1 EGFR MRC2	6.44e-07	192	166	8	8df15085b35b86f39debd933284cb703c5dd63c2
ToppCell	Mesenchymal-matrix_fibroblast_2_cell\|World / Lineage, Cell type, age group and donor	CFH COL5A2 DPT LAMA2 KCNT2 MRC2 KLHL13 CHRDL1	6.44e-07	192	166	8	a769158c49d2b208c4224d85e7ae68c85cc372ed
ToppCell	droplet-Fat-Scat-18m-Mesenchymal-Cd34+\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	COL5A2 DPT LAMA2 PTGFRN EGFR MRC2 CHRDL1 MME	6.70e-07	193	166	8	316ebdf15f75d88c348f909b643fcd315364ca84
ToppCell	RV-08._Macrophage\|RV / Chamber and Cluster_Paper	IL10RA MYO5A FRMD4B SCN9A ASPM IGSF21 MARCO TOP2A	6.70e-07	193	166	8	12bf98a280f87e4d8f0c6887dfc855da72e47ac1
ToppCell	droplet-Limb_Muscle-nan-3m-Mesenchymal\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYC COL5A2 DPT LAMA2 THBS3 MRC2 KLHL13 PCSK6	6.70e-07	193	166	8	eff718664fe0aaf89050efd9cc7b6dfb1df46666
ToppCell	droplet-Fat-Scat-18m-Mesenchymal\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	COL5A2 DPT LAMA2 PTGFRN EGFR MRC2 CHRDL1 MME	6.70e-07	193	166	8	8dc6db335678f3a5cfd36026ad811fed8d9cb4bc
ToppCell	droplet-Fat-Scat-18m-Mesenchymal-mesenchymal_stem_cell_of_adipose\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	COL5A2 DPT LAMA2 PTGFRN EGFR MRC2 CHRDL1 MME	6.70e-07	193	166	8	1afdd3f7d703f4204a2cbfe40e135ac7b09213f7
ToppCell	facs-BAT-Fat-3m-Mesenchymal-mesenchymal_progenitor\|BAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PCSK5 COL5A2 DPT LAMA2 THBS3 EGFR KLHL13 CHRDL1	6.97e-07	194	166	8	da45811ba07d746e7cba7ed78882b5d98ac7397d
ToppCell	facs-BAT-Fat-3m-Mesenchymal\|BAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PCSK5 COL5A2 DPT LAMA2 THBS3 EGFR KLHL13 CHRDL1	6.97e-07	194	166	8	76b8512fd92014b3ecc42b0a20d6d1df074cba2c
ToppCell	facs-BAT-Fat-3m-Mesenchymal-mesenchymal_stem_cell_of_adipose\|BAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PCSK5 COL5A2 DPT LAMA2 THBS3 EGFR KLHL13 CHRDL1	6.97e-07	194	166	8	ef0fa9daecd3bf43c6cf56345928cacdbee19779
ToppCell	facs-GAT-Fat-3m-Mesenchymal-mesenchymal_progenitor\|GAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CFH PCSK5 COL5A2 DPT LAMA2 EMILIN1 THBS3 EGFR	7.24e-07	195	166	8	69a29d03e664b72f32d41876510c62345c3aed31
ToppCell	LA-02._Fibroblast_II\|World / Chamber and Cluster_Paper	CFH PCSK5 COL5A2 TPST1 LAMA2 EGFR MRC2 PCSK6	7.24e-07	195	166	8	a78b605b49acd8c9d68716266ca269dafcd910b9
ToppCell	5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts-Alveolar_fibroblasts_L.2.1.1.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	COL5A2 DPT LAMA2 EMILIN1 ADAMTS12 MRC2 CHRDL1 MME	7.24e-07	195	166	8	df409f94f4e83be89f7a608058ee07ce3ce3a149
ToppCell	5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	COL5A2 DPT LAMA2 EMILIN1 ADAMTS12 MRC2 CHRDL1 MME	7.24e-07	195	166	8	4243190ad291d56694e2155954dbaa879c9d3844
ToppCell	facs-GAT-Fat-3m-Mesenchymal\|GAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CFH PCSK5 COL5A2 DPT LAMA2 EMILIN1 THBS3 EGFR	7.24e-07	195	166	8	1cffae2b08dbfa1c633ce24023e89b66d28b5431
ToppCell	facs-GAT-Fat-3m-Mesenchymal-mesenchymal_stem_cell_of_adipose\|GAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CFH PCSK5 COL5A2 DPT LAMA2 EMILIN1 THBS3 EGFR	7.24e-07	195	166	8	9cef6f18664518060af7c192310dddce6d70345a
ToppCell	IPF-Stromal-Myofibroblast\|World / Disease state, Lineage and Cell class	CFH COL5A2 DPT LAMA2 EMILIN1 ADAMTS12 KCNT2 MRC2	7.53e-07	196	166	8	7fc9894ceb79dab9f0495acc84e2d6d0d1c69bb7
ToppCell	IPF-Stromal-Myofibroblast\|IPF / Disease state, Lineage and Cell class	CFH COL5A2 DPT LAMA2 EMILIN1 ADAMTS12 KCNT2 MRC2	7.53e-07	196	166	8	2d0a48e49b3b37bb66e33e74c52915911e1f8a74
ToppCell	5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CFH COL5A2 DPT LAMA2 EMILIN1 ADAMTS12 MRC2 CHRDL1	7.53e-07	196	166	8	42e9828222a9663525d571633e8a454c30bfa7f8
ToppCell	COPD-Stromal\|COPD / Disease state, Lineage and Cell class	MYC CFH COL5A2 DPT LAMA2 EMILIN1 EGFR CHRDL1	7.82e-07	197	166	8	d5390d86acaa8c39f1da893e8d2271f9ed2951d7
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Collagen+matrisome-high_fibroblast-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	CFH COL5A2 LAMA2 EMILIN1 ADAMTS12 KCNT2 MRC2 CHSY3	7.82e-07	197	166	8	ae0435f4b4a9cdedb1c201fc56921048390097bf
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Collagen+matrisome-high_fibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	CFH COL5A2 LAMA2 EMILIN1 ADAMTS12 KCNT2 MRC2 CHSY3	7.82e-07	197	166	8	37f6b6f2809b952382eaebb642b0aad6371f4251
ToppCell	Fibroblasts-HLA-DRA_high_Fibroblasts\|World / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues	CFH PCSK5 COL5A2 DPT CFI EMILIN1 EGFR MRC2	8.12e-07	198	166	8	e8c0fbf306fae13e97caa294d7c99a564bd97130
ToppCell	Fetal_29-31_weeks-Mesenchymal\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	CFH COL5A2 TPST1 LAMA2 EMILIN1 ADAMTS12 KCNT2 MRC2	8.12e-07	198	166	8	21cf4d81386761d09d0f6829c01c198e5524176d
ToppCell	cellseq-Mesenchymal-Fibroblastic-Fibroblastic_2-AF1\|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	CFH COL5A2 DPT LAMA2 EMILIN1 ADAMTS12 MRC2 CHRDL1	8.12e-07	198	166	8	f1374f7a50244d59c766ac41f44c08c9117407d2
ToppCell	droplet-Limb_Muscle-MUSCLE-1m-Mesenchymal-nan\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	COL5A2 TPST1 DPT CADM4 LAMA2 PTGFRN MMEL1 PCSK6	8.12e-07	198	166	8	5e70246a9ce199cb2fb5379912b8ab59456219e4
ToppCell	distal-mesenchymal-Alveolar_Fibroblast-2\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	MYC CFH COL5A2 DPT LAMA2 EMILIN1 MRC2 CHRDL1	8.44e-07	199	166	8	28c1722deef3b8347371c7359be7c64b95780de3
ToppCell	368C-Fibroblasts-Fibroblast-D\|368C / Donor, Lineage, Cell class and subclass (all cells)	CFH COL5A2 TPST1 DPT LAMA2 EMILIN1 MRC2 CHRDL1	8.44e-07	199	166	8	66545eb7f65e450b742628fd431956e13330a0d3
ToppCell	Bronchial-10x5prime-Stromal-Fibroblastic-Fibro_myofibroblast\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	CFH COL5A2 DPT LAMA2 EMILIN1 MRC2 CHRDL1 ACSS3	8.44e-07	199	166	8	21335475bbfbad8a6943b8076a6c1c67f3eec5d3
ToppCell	(5)_Fibroblast-D\|World / Lung cell shreds - cell class (v4) and cell subclass (v4)	CFH COL5A2 TPST1 DPT ARID4A LAMA2 EMILIN1 CHRDL1	8.44e-07	199	166	8	3f415620ad8b8d8c6871e1353e13f87b281fcc0e
ToppCell	368C-Fibroblasts-Fibroblast-D-\|368C / Donor, Lineage, Cell class and subclass (all cells)	CFH COL5A2 TPST1 DPT LAMA2 EMILIN1 MRC2 CHRDL1	8.44e-07	199	166	8	5a425e7d11c5911ff5855c27a7f058a7ed7abbb0
ToppCell	cellseq-Mesenchymal-Fibroblastic-Fibroblastic_2\|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	CFH COL5A2 DPT LAMA2 EMILIN1 ADAMTS12 MRC2 CHRDL1	8.44e-07	199	166	8	66a79732caf2f04c09b4d9832377aa01ca477677
ToppCell	medial-mesenchymal-Alveolar_Fibroblast\|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	MYC CFH COL5A2 DPT FRAS1 EMILIN1 MRC2 CHRDL1	8.76e-07	200	166	8	c22cbfecee00183dd4be678f116ab9fd9ad0a4dd
ToppCell	distal-2-mesenchymal-Alveolar_Fibroblast\|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	MYC CFH COL5A2 DPT LAMA2 EMILIN1 MRC2 CHRDL1	8.76e-07	200	166	8	12b705dabec1b3752a488a891eda1a5123fcdc41
ToppCell	normal_Lung-Fibroblasts\|normal_Lung / Location, Cell class and cell subclass	MYC CFH COL5A2 DPT LAMA2 EMILIN1 MRC2 CHRDL1	8.76e-07	200	166	8	803cf7f1382d07220249029cd220233232027689
ToppCell	medial-2-mesenchymal-Alveolar_Fibroblast\|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	MYC CFH COL5A2 DPT FRAS1 EMILIN1 MRC2 CHRDL1	8.76e-07	200	166	8	cc6062dac07916c29091fc6bee2b864d29e6525b
ToppCell	proximal-mesenchymal-Adventitial_Fibroblast-3\|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	MYC CFH COL5A2 DPT LAMA2 EMILIN1 MRC2 CHRDL1	8.76e-07	200	166	8	05486d86868f6a93429226063cca270f00dd8714
ToppCell	medial-mesenchymal-Alveolar_Fibroblast-2\|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	MYC CFH COL5A2 DPT FRAS1 EMILIN1 MRC2 CHRDL1	8.76e-07	200	166	8	5c0716bf375c8158f7dc2c82bf5eaf37af594dd0
ToppCell	proximal-3-mesenchymal-Adventitial_Fibroblast\|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	MYC CFH COL5A2 DPT LAMA2 EMILIN1 MRC2 CHRDL1	8.76e-07	200	166	8	869d45b71efd395d050873db5fee2ed0443d5e6f
ToppCell	Parenchymal-10x5prime-Stromal-Fibroblastic-Fibro_myofibroblast\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	CFH COL5A2 DPT LAMA2 EMILIN1 ADAMTS12 MRC2 CHRDL1	8.76e-07	200	166	8	54806080b5e97859ee6a4a9b4f19e22021c218f5
ToppCell	distal-mesenchymal-Adventitial_Fibroblast\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	MYC CFH COL5A2 TPST1 DPT LAMA2 MRC2 CHRDL1	8.76e-07	200	166	8	687cfada2d0977e8985e0a73a5804f84f2ca9c52
ToppCell	Tracheal-NucSeq-Stromal-Fibroblastic-Fibro_peribronchial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	CFH COL5A2 DPT LAMA2 KCNT2 MRC2 KLHL13 CHSY3	8.76e-07	200	166	8	58b38f9a484ee94191091a0659ed62ebed2d4a14
ToppCell	Biopsy_Other_PF-Mesenchymal-Myofibroblasts\|Biopsy_Other_PF / Sample group, Lineage and Cell type	CFH COL5A2 DPT LAMA2 EMILIN1 ADAMTS12 MRC2 CHRDL1	8.76e-07	200	166	8	e504570fd7eec1524c401b1cfa9d10822d80d994
ToppCell	proximal-mesenchymal-Adventitial_Fibroblast\|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	MYC CFH COL5A2 DPT LAMA2 EMILIN1 MRC2 CHRDL1	8.76e-07	200	166	8	58c5870030192b337e7d883044948634fcd17d2c
ToppCell	medial-mesenchymal-Adventitial_Fibroblast\|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	MYC CFH DPT LAMA2 CFI EMILIN1 MRC2 CHRDL1	8.76e-07	200	166	8	87a5a0c252c08ba10316c21f6a9d5244c4d98c74
ToppCell	Tracheal-10x5prime-Stromal-Fibroblastic-Fibro_adventitial\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	PCSK5 COL5A2 TPST1 DPT LAMA2 EMILIN1 MRC2 CHRDL1	8.76e-07	200	166	8	74ad0ae592252060ee294d7483327d765a6ba1dd
ToppCell	medial-2-mesenchymal-Adventitial_Fibroblast\|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	MYC CFH DPT LAMA2 CFI EMILIN1 MRC2 CHRDL1	8.76e-07	200	166	8	6ccf44f10d2cee5f48b8f05bd9a1b94057184d56
ToppCell	normal_Lung-Fibroblasts-COL14A1+_matrix_FBs\|normal_Lung / Location, Cell class and cell subclass	MYC CFH COL5A2 DPT LAMA2 EMILIN1 MRC2 CHRDL1	8.76e-07	200	166	8	ee3d06865a6300e1279edf6664320b71647f5efb
ToppCell	medial-mesenchymal-Adventitial_Fibroblast-2\|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	MYC CFH DPT LAMA2 CFI EMILIN1 MRC2 CHRDL1	8.76e-07	200	166	8	5ee1318a74ca28a81bd81c20c611de84c17636b0
ToppCell	367C-Fibroblasts-Fibroblast-F\|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)	GPM6A GCNT3 MYO5B PCSK6 ASPM IGSF21 TOP2A	2.48e-06	161	166	7	c61283c301a87bb802f6f8ce79c26067032dd7d9
ToppCell	367C-Fibroblasts-Fibroblast-F-\|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)	GPM6A GCNT3 MYO5B PCSK6 ASPM IGSF21 TOP2A	2.48e-06	161	166	7	9864d8b0929dacf4be7a4e97d2527ac3120ea264
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast-proliferative_fibroblast\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	CFH COL5A2 LAMA2 EMILIN1 ADAMTS12 MRC2 CHSY3	3.42e-06	169	166	7	a84490724a206c9bbb145f7ce08613f91d100ac4
ToppCell	Control-Epithelial_cells-ECM-high_epithelial\|Control / group, cell type (main and fine annotations)	GPM6A ARHGEF12 NCKAP5 FNBP1L KCNT2 EGFR ST6GALNAC3	3.56e-06	170	166	7	e2023d66e70983c87dacbd6181d3426488d1fc57
ToppCell	frontal_cortex-Neuronal-GABAergic_neuron-Vip\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	ACADL INPP5F CSMD3 KCNT2 EGFR KLHL13 SEZ6	3.70e-06	171	166	7	5efd15300f865ebf651e0888265cbd717bc3b9d3
ToppCell	5'-Adult-Appendix-Mesenchymal-fibroblastic-Stromal_1_(CCL11+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CFH COL5A2 CSMD3 EMILIN1 TBC1D16 KCNT2 EGFR	4.15e-06	174	166	7	f90ca117b729436cf452e2ddcec26ba525c5c13b
ToppCell	facs-Marrow-B-cells-24m\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FRAS1 MZB1 LAMA2 CSMD3 KCNT2 IGSF21 WDR72	4.31e-06	175	166	7	887e75fc90e59a6394d62f3c048a9cfdf6707725
ToppCell	facs-Marrow-KLS-18m-Lymphocytic-early_pro_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PCSK5 DSCAM NCKAP5 CACNA2D4 TLR5 DNAH8 MPI	4.47e-06	176	166	7	7292e014b8f697f0c2e9f47c48333de95cb44a69
ToppCell	facs-Marrow-KLS-18m-Lymphocytic-early_pro-B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PCSK5 DSCAM NCKAP5 CACNA2D4 TLR5 DNAH8 MPI	4.47e-06	176	166	7	88ca2f83d8301633232735f39b0683efe49d0b86
ToppCell	343B-Fibroblasts-Fibroblast-B_(Myofibroblast)\|343B / Donor, Lineage, Cell class and subclass (all cells)	DPF1 CFH COL5A2 DPT CMYA5 KDM4D KCNT2	4.64e-06	177	166	7	e55d21d4d61a069b9bbe0e7595fbfb7cfbacfd87
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_1-Inh_L1-3_VIP_SSTR1\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PCSK5 DPT NCKAP5 KCNT2 EGFR DPF3 KLHL13	4.64e-06	177	166	7	fdab7b7ddfb06f913b8224c0c80574dc3cf4cbd4
ToppCell	343B-Fibroblasts-Fibroblast-B_(Myofibroblast)-\|343B / Donor, Lineage, Cell class and subclass (all cells)	DPF1 CFH COL5A2 DPT CMYA5 KDM4D KCNT2	4.64e-06	177	166	7	43ba6f12c2fb32698a420bf799d46ac1b558f146
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)\|Children_(3_yrs) / Lineage, Cell type, age group and donor	GPM6A FRAS1 DSCAM MYO5B PEBP4 EGFR CHSY3	5.00e-06	179	166	7	cb38b54261a7af5ee3347e64c8aa880a77ed0763
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Proximal_Tubule_Epithelial_Cell_Segment_1_/_Segment_2\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	ABAT NCKAP5 DPF3 SCN9A OSBPL6 MME WDR72	5.18e-06	180	166	7	1363b3254470f6ff98630d1df83a1bdbacc137e0
ToppCell	facs-Lung-3m-Mesenchymal-fibroblast-adventitial_fibroblast-adventitial_fibroblast_l17\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CFH DPT LAMA2 KCNT2 EGFR MRC2 PCSK6	5.18e-06	180	166	7	39ae8586efd91536e9ac6408d26de7e6d6237c41
ToppCell	390C-Fibroblasts-Fibroblast-G\|390C / Donor, Lineage, Cell class and subclass (all cells)	CFH DPT MASP1 FRAS1 EMILIN1 ADAMTS12 MRC2	5.18e-06	180	166	7	137fc14859c89e1ecd98bee388bb58c04b835847
ToppCell	390C-Fibroblasts-Fibroblast-G-\|390C / Donor, Lineage, Cell class and subclass (all cells)	CFH DPT MASP1 FRAS1 EMILIN1 ADAMTS12 MRC2	5.18e-06	180	166	7	cd6790de050151fedfa2c5ea6ad58b72665414b2
ToppCell	5'-Adult-LymphNode-Mesenchymal-fibroblastic-Transitional_Stromal_3_(C3+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	MYC DPT ACADL LAMA2 EGFR CHRDL1 SOD2	5.37e-06	181	166	7	ab66a89f316b935d9ba1277426d976b1e9e39757
ToppCell	5'-Adult-LargeIntestine-Mesenchymal-fibroblastic-Stromal_3_(C7+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	COL5A2 DPT TUSC3 LAMA2 CMYA5 EMILIN1 MRC2	5.57e-06	182	166	7	3dfa9187e9d2bab1d199079d29209c4648220ada
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FRAS1 PKD1L2 CSMD3 RYR3 SCN9A MYOM2 EPHA7	5.99e-06	184	166	7	2cbed6462fea2622871bb7e49b0df3d984239281
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast-kidney_interstitial_fibroblast_5\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	CFH COL5A2 LAMA2 ADAMTS12 MRC2 CHSY3 DNAH8	5.99e-06	184	166	7	c5436a8e45f471b8d1301abbe9c7879204537f52
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FRAS1 PKD1L2 CSMD3 RYR3 SCN9A MYOM2 EPHA7	5.99e-06	184	166	7	2b19a8c5f823e00812908b23e66bb4e563278aff
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FRAS1 PKD1L2 CSMD3 RYR3 SCN9A MYOM2 EPHA7	5.99e-06	184	166	7	ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCell	frontal_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Rxfp1_Prdm8\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	DPT MASP1 KLHL13 LHFPL5 MME IL23R	6.24e-06	121	166	6	2ae870f822488799cd0ad85e7f72af64e33a867f
ToppCell	droplet-Heart-4Chambers-18m-Mesenchymal-fibroblast\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CFH COL5A2 DPT DSCAM LAMA2 MRC2 PCSK6	6.42e-06	186	166	7	35c88cc4eb388811fcac4323b549e5897fa8dc27
ToppCell	droplet-Heart-4Chambers-18m-Mesenchymal-fibroblast_of_cardiac_tissue\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CFH COL5A2 DPT DSCAM LAMA2 MRC2 PCSK6	6.42e-06	186	166	7	d998c5b00083cf2a7cd5341a98b7374b4de73c63
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Proximal_Tubule_Epithelial_Cell_Segment_3\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ABAT NCKAP5 ACSS2 FRMD4B DPF3 OSBPL6 MME	6.42e-06	186	166	7	a417e1e21313a7e05951038cdef5ac672a9f727c
ToppCell	LA-01._Fibroblast_I\|World / Chamber and Cluster_Paper	PCSK5 COL5A2 DPT LAMA2 EGFR MRC2 PCSK6	6.65e-06	187	166	7	4ea486991f66c29728d127171a07b81404ec0b78
ToppCell	droplet-Pancreas-Exocrine-18m-Mesenchymal-pancreatic_stellate_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CFH COL5A2 DPT LAMA2 MRC2 CHRDL1 ACSS3	6.65e-06	187	166	7	4e553721fa5598cb211f44e3226280b7e6885484
Disease	sialic acid-binding Ig-like lectin 6 measurement	SIGLEC12 CFH CEACAM18	9.08e-06	8	163	3	EFO_0008285
Disease	Liver carcinoma	MYC GPM6A DCAF4L2 COMT UROC1 EGFR PIK3CA ASPM MARCO TOP2A HERC5 SOD2	2.71e-05	507	163	12	C2239176
Disease	Disease Exacerbation	MYC TXNIP EGFR PIK3CA TOP2A ALDH7A1 SOD2	3.86e-05	165	163	7	C0235874
Disease	attempted suicide	DPF1 PCSK5 COMT TUSC3 FYCO1 DNAH8 EPHA7	6.24e-05	178	163	7	EFO_0004321
Disease	Drusen, Radial, Autosomal Dominant	CFH CFI	9.07e-05	3	163	2	C1852021
Disease	Malattia Leventinese	CFH CFI	9.07e-05	3	163	2	C1852020
Disease	complement C3 measurement	CFH KCNT2	9.07e-05	3	163	2	EFO_0004983
Disease	DOYNE HONEYCOMB RETINAL DYSTROPHY	CFH CFI	9.07e-05	3	163	2	C1832174
Disease	alcohol use disorder (implicated_via_orthology)	DPF1 MAP4K3 DPF2 ACSS2 RYR3 EGFR DPF3	1.10e-04	195	163	7	DOID:1574 (implicated_via_orthology)
Disease	Malignant neoplasm of prostate	MYC COMT ATR ARID4A IGSF5 GCNT1 EGFR PIK3CA TLR5 MME TOP2A SOD2	1.71e-04	616	163	12	C0376358
Disease	Prostatic Neoplasms	MYC COMT ATR ARID4A IGSF5 GCNT1 EGFR PIK3CA TLR5 MME TOP2A SOD2	1.71e-04	616	163	12	C0033578
Disease	mitogen-activated protein kinase 12 measurement	CFH MAPK12	1.81e-04	4	163	2	EFO_0020576
Disease	n-acetylglucosamine-6-sulfatase measurement	CFH GNS	1.81e-04	4	163	2	EFO_0020586
Disease	HELLP Syndrome	CFH CFI	1.81e-04	4	163	2	C0162739
Disease	Diffuse Large B-Cell Lymphoma	MYC TXNIP PIK3CA SOD2	2.46e-04	55	163	4	C0079744
Disease	maple syrup urine disease (is_implicated_in)	DBT DLD	3.00e-04	5	163	2	DOID:9269 (is_implicated_in)
Disease	urinary bladder cancer (is_marker_for)	MYC COMT EGFR TOP2A SOD2	3.27e-04	107	163	5	DOID:11054 (is_marker_for)
Disease	atrophic macular degeneration	CFH CFI SOD2	3.48e-04	25	163	3	EFO_1001492
Disease	Schizophrenia	IL10RA GPM6A COMT MYO5B LAMA2 CHEK1 CMYA5 LILRB1 GFRA3 ADAMTS12 PTPN1 PIK3CA MCAT SOD2	4.10e-04	883	163	14	C0036341
Disease	Ulcerative Colitis	IL10RA GPR65 IL23R CXCR1	4.15e-04	63	163	4	C0009324
Disease	VACTERL association (implicated_via_orthology)	PCSK5 IFT172	4.48e-04	6	163	2	DOID:14679 (implicated_via_orthology)
Disease	Congenital cataract	FYCO1 TDRD7	4.48e-04	6	163	2	C0009691
Disease	triggering receptor expressed on myeloid cells 1 measurement	CFH TREML2	4.48e-04	6	163	2	EFO_0802161
Disease	interleukin-23 receptor measurement	CFH IL23R	4.48e-04	6	163	2	EFO_0801725
Disease	Maple Syrup Urine Disease	DBT DLD	4.48e-04	6	163	2	C0024776
Disease	alcohol dependence measurement, electroencephalogram measurement	UROC1 FRMD4B	6.25e-04	7	163	2	EFO_0004357, EFO_0007835
Disease	Squamous cell carcinoma of lung	ATR MAP4K3 EGFR	7.30e-04	32	163	3	C0149782
Disease	Malignant Neoplasms	MYC ATR EGFR PIK3CA SOD2	7.41e-04	128	163	5	C0006826
Disease	neurexophilin-1 measurement	CFH PCSK6	8.31e-04	8	163	2	EFO_0008244
Disease	atypical hemolytic-uremic syndrome (is_implicated_in)	CFH CFI	8.31e-04	8	163	2	DOID:0080301 (is_implicated_in)
Disease	nephroblastoma (is_marker_for)	MYC KDM4D TOP2A	8.73e-04	34	163	3	DOID:2154 (is_marker_for)
Disease	ovarian neoplasm	MYC ATR EGFR PIK3CA SOD2	9.10e-04	134	163	5	C0919267
Disease	Malignant neoplasm of ovary	MYC ATR EGFR PIK3CA SOD2	1.01e-03	137	163	5	C1140680
Disease	Adenocarcinoma of lung (disorder)	MYC ATR EGFR PIK3CA TOP2A SOD2	1.03e-03	206	163	6	C0152013
Disease	Atypical hemolytic-uremic syndrome	CFH CFI	1.06e-03	9	163	2	cv:C2931788
Disease	C3 glomerulopathy	CFH CFI	1.06e-03	9	163	2	C4087273
Disease	Hemolytic-uremic syndrome	CFH CFI	1.06e-03	9	163	2	cv:C0019061
Disease	complement factor B measurement	CFH KCNT2	1.06e-03	9	163	2	EFO_0008096
Disease	Bladder Neoplasm	MYC LAMA2 EGFR IGSF21 SOD2	1.11e-03	140	163	5	C0005695
Disease	Malignant neoplasm of urinary bladder	MYC LAMA2 EGFR IGSF21 SOD2	1.14e-03	141	163	5	C0005684
Disease	Congenital disorder of glycosylation	TUSC3 ALG13 MPI	1.21e-03	38	163	3	cv:C0282577
Disease	Atypical Hemolytic Uremic Syndrome	CFH CFI	1.33e-03	10	163	2	C2931788
Disease	age at onset, multiple sclerosis	PCSK5 NCKAP5	1.33e-03	10	163	2	EFO_0004847, MONDO_0005301
Disease	Head and Neck Carcinoma	EGFR PIK3CA	1.33e-03	10	163	2	C3887461
Disease	Glioma	ATR EGFR PIK3CA TOP2A	1.40e-03	87	163	4	C0017638
Disease	Myopia	FRAS1 MYO5B LAMA2 LILRB1 FRMD4B OSBPL6 PNPLA8 ALDH7A1	1.41e-03	385	163	8	HP_0000545
Disease	hemopexin measurement	CFH KCNT2	1.61e-03	11	163	2	EFO_0008149
Disease	ankylosing spondylitis	PCSK5 CHSY1 MYOM2 IL23R	1.65e-03	91	163	4	EFO_0003898
Disease	Non-Small Cell Lung Carcinoma	MYC CORO1C EGFR PIK3CA SOD2	1.79e-03	156	163	5	C0007131
Disease	psoriasis (is_marker_for)	CFH CFI SOD2	1.86e-03	44	163	3	DOID:8893 (is_marker_for)
Disease	Papilloma	EGFR SOD2	1.93e-03	12	163	2	C0030354
Disease	Papillomatosis	EGFR SOD2	1.93e-03	12	163	2	C0205875
Disease	Papilloma, Squamous Cell	EGFR SOD2	1.93e-03	12	163	2	C0205874
Disease	acute myeloid leukemia (implicated_via_orthology)	ARID4A TOP2A	1.93e-03	12	163	2	DOID:9119 (implicated_via_orthology)
Disease	dimethylglycine measurement	CSMD3 DPF3 PCSK6	2.11e-03	46	163	3	EFO_0010476
Disease	Short Rib-Polydactyly Syndrome	IFT172 WDR35	2.27e-03	13	163	2	C0036996
Disease	transmembrane protein 87B measurement	CFH PCSK6	2.27e-03	13	163	2	EFO_0802158
Disease	complement factor H-related protein 4 measurement	CFH KCNT2 ASPM	2.53e-03	49	163	3	EFO_0600091
Disease	Neoplasm of lung	EGFR PIK3CA	2.64e-03	14	163	2	cv:C0024121
Disease	Lung cancer	EGFR PIK3CA	2.64e-03	14	163	2	cv:C0242379
Disease	LUNG CANCER	EGFR PIK3CA	2.64e-03	14	163	2	211980
Disease	Majewski Syndrome	IFT172 WDR35	2.64e-03	14	163	2	C0024507
Disease	wet macular degeneration	CFH CFI	2.64e-03	14	163	2	EFO_0004683
Disease	Saldino-Noonan Syndrome	IFT172 WDR35	2.64e-03	14	163	2	C0036069
Disease	polycystic kidney disease (implicated_via_orthology)	IFT172 KIF3A	2.64e-03	14	163	2	DOID:0080322 (implicated_via_orthology)
Disease	Squamous cell carcinoma of the head and neck	EGFR PIK3CA SOD2	3.00e-03	52	163	3	C1168401
Disease	mannan-binding lectin serine protease 1 measurement	CFH MASP1	3.04e-03	15	163	2	EFO_0008223
Disease	plasminogen activator inhibitor 1 measurement	FRMD4B TMEM232 MYOM2	3.34e-03	54	163	3	EFO_0004792
Disease	diffuse plaque measurement	PCSK5 ABAT TUSC3 ANO10 CSMD3 FRMD4B OSBPL6 CHSY3 KIR3DL2 EPHA7 WDR72	3.38e-03	758	163	11	EFO_0010699
Disease	Polyposis, Adenomatous Intestinal	EGFR SOD2	3.46e-03	16	163	2	C2713442
Disease	Familial Intestinal Polyposis	EGFR SOD2	3.46e-03	16	163	2	C2713443
Disease	sarcoidosis (is_implicated_in)	CFH IL23R	3.46e-03	16	163	2	DOID:11335 (is_implicated_in)
Disease	pancreatic cancer (is_implicated_in)	ATR CHEK1 EGFR SOD2	3.51e-03	112	163	4	DOID:1793 (is_implicated_in)
Disease	ovarian cancer (is_implicated_in)	COMT PIK3CA SOD2	3.70e-03	56	163	3	DOID:2394 (is_implicated_in)
Disease	complement factor H-related protein 1 measurement	CFH KCNT2 ASPM	3.70e-03	56	163	3	EFO_0600054
Disease	Prescription Drug Abuse	DSCAM EIPR1 CSMD3 DNAH8	3.86e-03	115	163	4	C4316881
Disease	Substance-Related Disorders	DSCAM EIPR1 CSMD3 DNAH8	3.86e-03	115	163	4	C0236969
Disease	Organic Mental Disorders, Substance-Induced	DSCAM EIPR1 CSMD3 DNAH8	3.86e-03	115	163	4	C0029231
Disease	Drug habituation	DSCAM EIPR1 CSMD3 DNAH8	3.86e-03	115	163	4	C0013170
Disease	Drug abuse	DSCAM EIPR1 CSMD3 DNAH8	3.86e-03	115	163	4	C0013146
Disease	Drug Use Disorders	DSCAM EIPR1 CSMD3 DNAH8	3.86e-03	115	163	4	C0013222
Disease	Drug Dependence	DSCAM EIPR1 CSMD3 DNAH8	3.86e-03	115	163	4	C1510472
Disease	Substance Dependence	DSCAM EIPR1 CSMD3 DNAH8	3.86e-03	115	163	4	C0038580
Disease	Substance Use Disorders	DSCAM EIPR1 CSMD3 DNAH8	3.86e-03	115	163	4	C0038586
Disease	Carcinoma in situ of stomach	ATR PIK3CA	3.91e-03	17	163	2	C0154060
Disease	Benign neoplasm of stomach	ATR PIK3CA	3.91e-03	17	163	2	C0153943
Disease	Neoplasm of uncertain or unknown behavior of stomach	ATR PIK3CA	3.91e-03	17	163	2	C0496905
Disease	Kuhnt-Junius degeneration (is_implicated_in)	CFI SOD2	3.91e-03	17	163	2	DOID:10873 (is_implicated_in)
Disease	Adenomatous Polyposis Coli	EGFR SOD2	3.91e-03	17	163	2	C0032580
Disease	Adenocarcinoma	MYC EGFR PIK3CA SOD2	3.98e-03	116	163	4	C0001418
Disease	Carcinoma, Granular Cell	MYC EGFR PIK3CA SOD2	3.98e-03	116	163	4	C0205644
Disease	Adenocarcinoma, Tubular	MYC EGFR PIK3CA SOD2	3.98e-03	116	163	4	C0205645
Disease	Adenocarcinoma, Oxyphilic	MYC EGFR PIK3CA SOD2	3.98e-03	116	163	4	C0205642
Disease	Carcinoma, Cribriform	MYC EGFR PIK3CA SOD2	3.98e-03	116	163	4	C0205643
Disease	Adenocarcinoma, Basal Cell	MYC EGFR PIK3CA SOD2	3.98e-03	116	163	4	C0205641
Disease	Substance abuse problem	DSCAM EIPR1 CSMD3 DNAH8	3.98e-03	116	163	4	C0740858
Disease	Polydactyly	FRAS1 IFT172 KIF3A PIK3CA	4.10e-03	117	163	4	C0152427
Disease	cortical thickness change measurement	FRMD4B EPHA7	4.38e-03	18	163	2	EFO_0021501
Disease	Adrenocortical carcinoma	EGFR TOP2A	4.38e-03	18	163	2	C0206686
Disease	Age-related macular degeneration	CFH CFI	4.38e-03	18	163	2	cv:C0242383

Protein segments in the cluster

Peptide	Gene	Start	Entry
CLTKWNRAIETMYNQ	TPST1	211	O60507
LAWEQMGRYRCTVEN	CEACAM18	286	A8MTB9
CMDANNVTYVWGVVS	CFI	531	P05156
KSSNQNRMEEWGACY	ALG13	411	Q9NP73
CDNIDSGAVWKQIYM	ARID4A	356	P29374
LQMCAWSISVEKGYN	CSMD3	2481	Q7Z407
GYQWKKSCMNQVTIS	CHEK1	401	O14757
CMAKYWASELQNSVA	ACADL	366	P28330
DAWKQYMRRSTCTIN	ALDH7A1	511	P49419
VAYMWGENSAGQCAV	ALS2	111	Q96Q42
TLNYGMERVWCVASL	COPB2	266	P35606
CTWEFGAMVNYIKKT	ABHD2	181	P08910
GVAQNNCYIWMEKTH	DPF1	46	Q92782
NSYTAQCVKMRYGVW	FAM47DP	301	A6NHR8
LRSWQKAVFYCGMAV	CACFD1	96	Q9UGQ2
MIYNVSWNRNGSLIC	CORO1C	176	Q9ULV4
KEGSDRQWNYACMPT	DPT	66	Q07507
RISEENETTCYMGKW	CFH	906	P08603
IFIEWMKGATTNICY	ACSS2	91	Q9NR19
KTTQIPQWCVEYMRS	DHX15	166	O43143
FRAWTAGRKQCMEYI	ASPM	1931	Q8IZT6
GVMIQEWYKASGLAC	ASPM	2791	Q8IZT6
LGAYWRRVECSTQMD	ADAMTS12	1331	P58397
VQQRWGAMEYSCFEI	ARHGEF12	1476	Q9NZN5
IDKYWECMTTRQRPG	ASH2L	201	Q9UBL3
KNLNNSMWGSAVYLC	DENND4A	181	Q7Z401
YRWCSNKKNAAVMDQ	KIR3DL2	361	P43630
QIWSIVRKYMQKEGC	KIAA0895L	221	Q68EN5
VILELWKRGCANMTY	ANO10	256	Q9NW15
GEVYKAQIMNVSWSA	DBT	436	P11182
RCINLWKYALDMQQS	FEM1C	356	Q96JP0
WLYVMNNCLLSISGK	MAP4K3	606	Q8IVH8
NRVMEKGSLKCAQYW	PTPN1	111	P18031
TALMWACYKGRTDVV	KIDINS220	106	Q9ULH0
QKTSWTCLLDGMQYF	KIAA0100	1621	Q14667
WRYKVTADFMAQACL	MDN1	2941	Q9NU22
QCIVYFWQGREASNM	FLII	981	Q13045
VRYQDEMWKGSACEF	FRAS1	291	Q86XX4
AKAAQDYCGMAWSVL	ENTPD7	441	Q9NQZ7
DYCGMAWSVLTQRFK	ENTPD7	446	Q9NQZ7
QKEWVMAGYQFLDRC	MTMR10	436	Q9NXD2
LISSWFRGNMQKKCY	MYO1A	726	Q9UBC5
TGVAQNNCYIWMEKR	DPF3	46	Q92784
VSQQRYERACWMKSS	MTO1	521	Q9Y2Z2
LQQCFMNTKVTSDWY	FYCO1	121	Q9BQS8
EKVYWTCRDQARMGC	FLYWCH1	446	Q4VC44
KAAGEKVYWMCRDQA	FLYWCH1	621	Q4VC44
SANWAYVKDACRMQK	GPM6A	236	P51674
SVMYSTRKNCAQLWL	KMT5B	251	Q4FZB7
CSNENALKTIFMWYR	ABAT	166	P80404
VYKICAWMQLAAATG	LHFPL5	126	Q8TAF8
YVPNRKVNSMCWASL	DCAF4L2	121	Q8NA75
WTRSSQNLVMVHKCY	TMEM63C	481	Q9P1W3
CQSDMNIEGAWKRGY	PCSK5	146	Q92824
RSEMNVQAAWKRGYT	PCSK6	181	P29122
VPDCNNYRQKITSWM	PEBP4	61	Q96S96
CDIKKGVSWNTVRYM	DNAH8	4096	Q96JB1
ATWRRCANYVNGNME	MME	406	P08473
KVRWNACYAMGNVFK	HEATR6	971	Q6AI08
ATPRWIDYGKMASQC	KDM4D	296	Q6B0I6
KIYVVGGYSWNNRCM	KLHL9	546	Q9P2J3
NCSWYIQGDRGDMIT	LRP3	71	O75074
KCVYMTASREDWGDQ	MRC2	926	Q9UBG0
RCQSSYWTYGKIQDM	LAMA2	526	P24043
GMWSKEECISLTRQY	IL10RA	216	Q13651
QWQKMYGRCSGNEVY	KCNT2	476	Q6UVM3
SLKRACYDTVNNMLW	HECTD4	166	Q9Y4D8
EWQLKCVAYTGNNMR	KIF3A	616	Q9Y496
WRECVGYVNSNMENA	MMEL1	436	Q495T6
CSVGEWLQAIKMERY	EPHA7	926	Q15375
CAVQQYAWGKMGSNS	MPI	11	P34949
CKLTFVKVNYWNSNM	OSBPL6	761	Q9BZF3
GWDTRSMSQIYCIEN	EIPR1	211	Q53HC9
SVKWNSRDEVAQMYC	PIK3CA	571	P42336
WVQYQCREALQLMVS	PKD1L2	246	Q7Z442
QEWKATVNMYRASGL	IFT172	1056	Q9UG01
QYSVIMRWGVCTVLA	OR2A5	131	Q96R48
LSMSGNIYSWGKNEC	HERC5	206	Q9UII4
AILKSCNMQAWKSYS	MCAT	356	Q8IVS2
CNMQAWKSYSAVDVL	MCAT	361	Q8IVS2
TYCEQKEWAMNVGDK	COMT	81	P21964
QVLRTWCGLQDVYQM	FRMD4B	41	Q9Y2L6
SQYLLNWCVQIAKGM	EGFR	811	P00533
YGRNESWLCFTMEVV	APOBEC3F	211	Q8IUX4
YNEMVGECWLQSARV	ATR	1916	Q13535
CNFKTDGRMREIVWY	IGSF21	46	Q96ID5
ARFNCTVSQGWKLIM	IGSF5	56	Q9NSI5
SWNNRCMVEIVQKYD	KLHL13	596	Q9P2N7
KYNPRTNKWVAASCM	KLHL17	596	Q6TDP4
LQEGRKAQQYLDMCW	FNBP1L	116	Q5T0N5
WKIFTEGEAQISQMC	CHRDL1	416	Q9BU40
RMKNQVACLDIYWTV	GFRA3	106	O60609
SYMREKAVSPNCWNV	EPM2AIP1	261	Q7L775
RMKWIACNNKGYYTQ	CACNA2D4	441	Q7Z3S7
DRCYQVWVMAVNFTG	CMYA5	3776	Q8N3K9
GSCTVRWENKTMYCI	DYNLT1	91	P63172
RWENKTMYCIVSAFG	DYNLT1	96	P63172
VYASWSRVQADLNCM	GCNT3	196	O95395
NMTCTWNAGKLTYID	IL23R	141	Q5VWK5
VCYEVLGNDTAKWRM	CXCR1	186	P25024
LVGMVWCSVRQKGSY	CADM4	341	Q8NFZ8
CTQNGQMYLNRDIWK	COL5A2	41	P05997
MQSWSRVYCSLAKRG	DLD	1	P09622
WQNSDAIVFCRMLGY	MARCO	451	Q9UEW3
TYACVRTMSALWNLQ	GNS	451	P15586
IYTCSAQGVWMNKVL	MASP1	411	P48740
KTVTDMEWRCCQGYG	EMILIN1	111	Q9Y6C2
TQLVKWMLGCYDALQ	HORMAD1	76	Q86X24
VYASWSRVQADLNCM	GCNT1	186	Q02742
KCNRIYQIMWANNGD	INPP5F	496	Q9Y2H2
IWGQSLREYMCVDRS	METTL17	206	Q9H7H0
MTKDWNYLEGSQKDC	KRBA2	46	Q6ZNG9
KLACSNTQVNGWVMF	OR1E3	186	Q8WZA6
GKLSVSQWAFCMENI	PPEF1	501	O14829
GCQYKMWQAIRASSA	PNPLA8	596	Q9NP80
ATWYELQMRVCNSAG	DSCAM	1541	O60469
QVSDAGLYRCMVTAW	PTGFRN	646	Q9P2B2
EDTWAYCQDTRKGMK	FAM47E	156	Q6ZV65
TMVALKLQDSGRYWC	TREML2	91	Q5T2D2
KLQDSGRYWCMRNTS	TREML2	96	Q5T2D2
CQSQGWMQTFLLTKE	LILRB1	346	Q8NHL6
ITKWGYKDCMNSNEG	NCKAP5	421	O14513
KNIIIQDCMWSGFSA	MYC	126	P01106
SVQCLDMYGIQSEWR	PKDREJ	1101	Q9NTG1
QVATFKGWTIIMYAA	SCN9A	1401	Q15858
SSCIWRMNNAPTKGY	ST6GALNAC3	101	Q8NDV1
CNMTLKGVVWYQGES	SIAE	266	Q9HAT2
AVYEMLQCFWVKSGR	SLC25A41	261	Q8N5S1
MLIRVNNDGTYCANW	MYCBP2	2401	O75592
KGYVLITCSWQNEMQ	RNASE9	161	P60153
GVKCNQWSEEASMVF	TDRD7	1026	Q8NHU6
VCKMYTARWVTNNDS	SNAPC3	356	Q92966
AGTYVFCVERGNMKW	SIGLEC12	116	Q96PQ1
RTYCDVWMIQNGTLI	ABCD3	96	P28288
STRWFVEGMLNICYN	ACSS3	101	Q9H6R3
RFAGVQCVWSYEMQQ	CHSY1	261	Q86X52
RFGGTQCVWSYEMQQ	CHSY3	351	Q70JA7
NFTEWKRSCALQMKY	CLEC9A	81	Q6UXN8
ATMNKGGTWNDLSCY	CLEC17A	351	Q6ZS10
TYGCQMNVNDTEIAW	CDK5RAP1	106	Q96SZ6
FVSSIKNGMWCRGTI	RNF17	471	Q9BXT8
MQTRSYSGWKLCENC	ZNF562	116	Q6V9R5
YNKTGWAMVSLCIVF	TUSC3	226	Q13454
TFKMQYDRTCEWTGL	WDR82	186	Q6UXN9
ANAWRYCTKVFDMLT	PPP6C	136	O00743
WSGNQKAYEIICQTM	UROC1	636	Q96N76
SVKRSNCYMVWGGDI	RYR3	1381	Q15413
NCYMVWGGDIVASSQ	RYR3	1386	Q15413
KMSENCDQVVWTGYY	TMEM232	421	C9JQI7
FMVWNSIGIIRCYND	WDHD1	446	O75717
SDVFQQWKYCTEMQL	TBC1D16	346	Q8TBP0
WDLCNSGMIKDYSGV	WDR72	846	Q3MJ13
TGVAQSNCYIWMEKR	DPF2	46	Q92785
GYQVVGSSVLMCQWD	SEZ6	741	Q53EL9
NVINWENVTERYMAC	SOD2	206	P04179
SGRFYVVMWKQTEQT	THBS3	801	P49746
CFVTETGRYDMWNIL	GPR65	291	Q8IYL9
QVISICWAAMGSLYA	TMEM262	61	E9PQX1
RWEVCLTMSEKGFQQ	TOP2A	296	P11388
AGYSRMVKVWDCNTG	WDR38	251	Q5JTN6
GVCNNYWKEKRQNDM	TRIM51G	356	A0A3B3IT33
LWYQVALSMVACGKS	TTC7A	416	Q9ULT0
MQLQVFWTGLEYTCR	TMEM72	1	A0PK05
VQLYAADRNCMWSKK	WASL	46	O00401
NSLYSRVSVDWGKCM	TLR5	206	O60602
WMQGSQQCKQTSEYL	TXNIP	56	Q9H3M7
MSWNADGQKICIVYE	WDR35	121	Q9P2L0
SCYAVWKMVGQRRVP	ZNF593OS	46	A0A0U1RRA0
SCRDFAKYEWIGQLM	HECTD3	591	Q5T447
MRYTQTVDIWSVGCI	MAPK12	201	P53778
RLCQVAAKGIWTMTY	NLRP14	426	Q86W24
MGRKVTVATCALNQW	NADSYN1	1	Q6IA69
CSWSKGMQIRYNVSQ	MYO5A	1711	Q9Y4I1
KDVCSWSTGMQLRYN	MYO5B	1701	Q9ULV0
WERMSVKLCFTVQGF	MYOM2	166	P54296
DACRAVAYQMWQNLA	MZB1	51	Q8WU39